银杏内酯在吉兰-巴雷综合征和实验性自身免疫性神经炎中的治疗作用。
The therapeutic effects of ginkgolides in Guillain-Barré syndrome and experimental autoimmune neuritis.
机构信息
Neuroscience Center, Department of Neurology, The First Hospital of Jilin University, Jilin University, Changchun, China.
Neuroscience Center, Department of Neurology, The First Hospital of Jilin University, Jilin University, Changchun, China.
出版信息
J Clin Neurosci. 2021 May;87:44-49. doi: 10.1016/j.jocn.2021.02.016. Epub 2021 Mar 11.
BACKGROUND
Guillain-Barré syndrome (GBS) is an acquired immune-mediated inflammatory peripheral neuropathy. The immune regulation of ginkgolides have been revealed in recent years. We herein investigate the potential therapeutic effects of ginkgolides both on GBS and its animal model, experimental autoimmune neuritis (EAN).
METHODS
EAN in C57BL/6 mice induced by subcutaneous injection with peripheral nerve myelin P0 protein peptide 180-199 (P0 peptide) were treated with ginkgolides at three different doses. GBS patients were randomly divided into two groups, the experimental group and the control group. The experimental group were treated with ginkgolides as soon as diagnosed.
RESULTS
Our data indicated that ginkgolides administration daily ameliorated the score of EAN and delayed the peak of disease in EAN mice. Ginkgolides also down-regulated the proportions of T helper (Th) 17 cells in EAN spleens. Furthermore, we also found that administration of ginkgolides significantly decreased the levels of interferon (IFN)-γ and interleukin-12 (IL)-12 in GBS patients.
CONCLUSIONS
Our results suggested that ginkgolides ameliorated the clinical score of EAN through down-regulating the proportions of Th 17 cells. Ginkgolides also suppressed inflammation response by decreasing pro-inflammatory cytokines IFN-γ and IL-12, suggesting ginkgolides had potential therapeutic effects on GBS patients and EAN in the future.
背景
格林-巴利综合征（GBS）是一种获得性免疫介导的炎症性周围神经病。近年来，银杏内酯的免疫调节作用已被揭示。我们在此研究银杏内酯对 GBS 及其动物模型实验性自身免疫性神经炎（EAN）的潜在治疗作用。
方法
通过皮下注射周围神经髓鞘 P0 蛋白肽 180-199（P0 肽）在 C57BL/6 小鼠中诱导 EAN，用三种不同剂量的银杏内酯进行治疗。GBS 患者随机分为两组，实验组和对照组。实验组在确诊后立即给予银杏内酯治疗。
结果
我们的数据表明，银杏内酯的每日给药可改善 EAN 的评分并延迟 EAN 小鼠疾病的高峰期。银杏内酯还下调了 EAN 脾脏中辅助性 T 细胞（Th）17 细胞的比例。此外，我们还发现，银杏内酯的给药显著降低了 GBS 患者的干扰素（IFN）-γ和白细胞介素-12（IL）-12 的水平。
结论
我们的结果表明，银杏内酯通过下调 Th17 细胞的比例改善了 EAN 的临床评分。银杏内酯还通过降低促炎细胞因子 IFN-γ和 IL-12 来抑制炎症反应，这表明银杏内酯对 GBS 患者和 EAN 具有潜在的治疗作用。
Zotero 插件